A population-based propensity-matched cohort study evaluating cardiovascular outcomes after tixagevimab/cilgavimab use for pre-exposure prophylaxis against COVID-19
Latest Information Update: 22 Nov 2022
At a glance
- Drugs Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 22 Nov 2022 New trial record
- 16 Nov 2022 Results published in the Clinical Infectious Diseases